Article
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
Lancet (London, England) - 29 Nov 2025
Ziegler Anette-Gabriele, Achenbach Peter, Weiß Andreas, Berner Reinhard, Casteels Kristina, Elding Larsson Helena, Haupt Florian, Hommel Angela, Jacobs An, Kordonouri Olga, Lundgren Markus, Ołtarzewski Mariusz, Pfirrmann Markus, Snape Matthew D, Szypowska Agnieszka, Todd John A, Vatish Manu, von dem Berge Thekla, Winkler Christiane, Bonifacio Ezio
Abstract excerpt
BACKGROUND: Type 1 diabetes begins with autoimmunity against pancreatic islet antigens, including insulin. The aim of the Primary Oral Insulin Trial (POInT) was to evaluate the efficacy and safety of daily high-dose oral insulin to prevent the development of islet autoantibodies and diabetes. METHODS: In this randomised, controlled, primary prevention trial, genetic screening in seven obstetric and paediatric...
Read the complete abstract on PubMedTopics
- Child
- Child, Preschool
- Female
- Humans